Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
UnpSiNPs (undecylenic acid-functionalized porous silicon nanoparticles) are an experimental nanomedicine platform designed for the targeted delivery of therapeutic agents, particularly for the treatment of glioblastoma multiforme (GBM). These nanoparticles consist of a porous silicon core that has been surface-modified with undecylenic acid (UA) to enhance stability and provide reactive sites for the attachment of targeting ligands and therapeutic payloads. In preclinical studies, UnpSiNPs are often conjugated with transferrin (Tf) to exploit receptor-mediated transcytosis across the blood-brain barrier (BBB) and are loaded with chemotherapy drugs like doxorubicin or gene therapies like antisense oligonucleotides. The platform aims to overcome the physiological barriers of the central nervous system, allowing for high-payload delivery directly to tumor sites while minimizing systemic toxicity.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on UnpSiNPs.